Abstract
Full text links
Free to read at www.jimmunol.org
http://www.jimmunol.org/cgi/content/abstract/144/12/4641
Citations & impact
Impact metrics
Citations of article over time
Alternative metrics
Discover the attention surrounding your research
https://www.altmetric.com/details/141483029
Article citations
Making a Monkey out of Human Immunodeficiency Virus/Simian Immunodeficiency Virus Pathogenesis: Immune Cell Depletion Experiments as a Tool to Understand the Immune Correlates of Protection and Pathogenicity in HIV Infection.
Viruses, 16(6):972, 17 Jun 2024
Cited by: 0 articles | PMID: 38932264 | PMCID: PMC11209256
Review Free full text in Europe PMC
Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field.
Viral Immunol, 31(2):195-203, 16 Jan 2018
Cited by: 22 articles | PMID: 29336703 | PMCID: PMC5863081
Review Free full text in Europe PMC
A brief history of the global effort to develop a preventive HIV vaccine.
Vaccine, 31(35):3502-3518, 21 May 2013
Cited by: 73 articles | PMID: 23707164
Review
Structure-based vaccine design in HIV: blind men and the elephant?
Curr Pharm Des, 16(33):3744-3753, 01 Jan 2010
Cited by: 28 articles | PMID: 21128885 | PMCID: PMC3096478
Review Free full text in Europe PMC
Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses.
Virology, 380(2):285-295, 18 Sep 2008
Cited by: 30 articles | PMID: 18804254 | PMCID: PMC3739291
Go to all (83) article citations
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1.
J Virol, 72(12):9855-9864, 01 Dec 1998
Cited by: 50 articles | PMID: 9811721 | PMCID: PMC110497
Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.
J Virol, 66(9):5210-5215, 01 Sep 1992
Cited by: 18 articles | PMID: 1380094 | PMCID: PMC289073
High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
AIDS Res Hum Retroviruses, 7(10):831-838, 01 Oct 1991
Cited by: 43 articles | PMID: 1720630
Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140.
J Virol, 72(12):9656-9667, 01 Dec 1998
Cited by: 21 articles | PMID: 9811699 | PMCID: PMC110475